**Highlights of This Issue** 2547

**REVIEW**

2549  It’s About Time: Lessons for Solid Tumors from Chronic Myelogenous Leukemia Therapy
Jason R. Westin and Razelle Kurzrock

**THERAPEUTIC DISCOVERY**

2556  Restoration of miR-200c to Ovarian Cancer Reduces Tumor Burden and Increases Sensitivity to Paclitaxel
Diana M. Cittelly, Irina Dimitrova, Erin N. Howe, Dawn R. Cochrane, Annie Jean, Nicole S. Spoelstra, Miriam A. Post, Xian Lu, Russell R. Broaddus, Monique A. Spillman, and Jennifer K. Richer

2566  Dual Systemic Tumor Targeting with Ligand-Directed Phage and Grp78 Promoter Induces Tumor Regression
Azadeh Kia, Justyna M. Przystal, Nastasia Nianiaris, Nicholas D. Mazarakis, Paul J. Mintz, and Amin Hajitou

2578  DLL4-Fc, an Inhibitor of DLL4-Notch Signaling, Suppresses Liver Metastasis of Small Cell Lung Cancer Cells through the Downregulation of the NF-κB Activity

**PRECLINICAL DEVELOPMENT**

2600  RSK2Ser227 at N-Terminal Kinase Domain Is a Potential Therapeutic Target for Multiple Myeloma
Yuji Shimura, Junya Kuroda, Masaki Ri, Hisao Nagoshi, Mio Yamamoto-Sugitani, Tsutomu Kobayashi, Miki Kyiota, Ryuko Nakayama, Shinsuke Mizutani, Yoshiaki Chinen, Natsumi Sakamoto, Yosuke Matsumoto, Shigeo Horiike, Yukimasa Shiotzu, Shinsuke Iida, and Masafumi Taniwaki

2609  Sorafenib-Mediated Targeting of the AAA-ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
Ping Yi, Arisa Higa, Said Taouji, Mariana G. Bexiga, Esther Marza, Daniela Arma, Claire Castain, Brigitte Le Bail, Jeremy C. Simpson, Jean Rosenbaum, Charles Balabaud, Paulette Bioulac-Sage, Jean-Frédéric Blanc, and Eric Chevet

2588  Targeting Olfactomedin-like 3 Inhibits Tumor Growth by Impairing Angiogenesis and Pericyte Coverage
Marijana Miljkovic-Licina, Philippe Hammel, Sarah Garrido-Urbani, Boris P.-L. Lee, Mehdi Meguenani, Chiraz Chaabane, Marie-Luce Bochaton-Piallat, and Beat A. Imhof

2610  Contrary Regulation of Bladder Cancer Cell Proliferation and Invasion by Dexamethasone-Mediated Glucocorticoid Receptor Signals
Yichun Zheng, Koji Izumi, Yi Li, Hitoshi Ishiguro, and Hiroshi Miyamoto

2621  Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib
Jaime Acquaviva, Donald L. Smith, Jim Sang, Julie C. Friedland, Suqin He, Manuel Sequeira, Chaohua Zhang, Yumiko Wada, and David A. Proia

2633  Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib
Jaime Acquaviva, Donald L. Smith, Jim Sang, Julie C. Friedland, Suqin He, Manuel Sequeira, Chaohua Zhang, Yumiko Wada, and David A. Proia

2644  BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer
Niranjan Awasthi, Changhua Zhang, Winston Ruan, Margaret A. Schwarz, and Roderich E. Schwarz

2654  Targeting the Inhibitor of Apoptosis Proteins as a Novel Therapeutic Strategy in Medulloblastoma
Joanna Keating, Maria Tsoli, Andrew R. Hallahan, Wendy J. Ingram, Michelle Haber, and David S. Ziegler
Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
Matthias Friedrich, Tobias Raum, Ralf Lutterbuese, Markus Voelkel, Petra Deegen, Doris Rau, Roman Kischel, Patrick Hoffmann, Christian Brandl, Joachim Schuhmacher, Peter Mueller, Ricardo Finnern, Melanie Fuergut, Dieter Zopf, Jerry W. Sloatstra, Patrick A. Baeverlein, Benno Rattel, and Peter Kufer

Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production

Development of Gene Expression–Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors
Jérôme Moreaux, Thierry Réme, Wim Leonard, Jean-Luc Veyrune, Guilhem Requinand, Hartmut Goldschmidt, Dirk Hose, and Bernard Klein

Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts
Angela Romanelli, Anderson Clark, Franck Assayag, Sophie Chateau-Joubert, Marie-France Poupon, Jean-Luc Servely, Jean-Jacques Fontaine, Xiaohong Liu, Edward Spooner, Samantha Goodstal, Patricia de Cremoux, Ivan Bèche, Didier Decaudin, and Elisabetta Marangoni

Spotlight on Clinical Response

Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine
James S. Wilmott, Varsha Tembe, Julie R. Howle, Rajshwa Sharma, John F. Thompson, Helen Rizos, Roger S. Lo, Richard F. Kefferd, Richard A. Scodyer, and Georgina V. Long

Acknowledgment to Reviewers

About the Cover
Olfactomedin-like 3 (Olfm3), a proangiogenic cue and a BMP4 agonist, is produced by both tumor endothelial cells and accompanying pericytes and deposited in the perivascular compartment. Blocking Olfm3 regresses the tumor vasculature, decreases pericycle coverage, and inhibits the progression of tumors. Olfm3 blockade provides an alternative strategy to control tumor growth by targeting a single molecule that affects two distinct cell types within the tumor microenvironment. For details, see article by Miljkovic-Licina and colleagues on page 2588.